Inovio revamps China deal; nets $23M upfront payment

Inovio Pharmaceuticals Inc. entered into an amended agreement Tueday that provides ApolloBio Corp. with the exclusive right to develop and commercialize Inovio's experimental DNA immunotherapy product in and around China. The amended deal covers the rights to Inovio's VGX-3100 product as a potential treatment for pre-cancers caused by human papillomavirus (HPV) in China, Hong Kong, Macao and Taiwan. HPV is the most common sexually transmitted infection and is the main cause of cervical cancer.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news